Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2025 06:30 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Patients achieved a mean 6.7 kPa reduction in liver stiffness as measured by vibration-controlled transient elastography (VCTE); this represents the largest reduction in liver stiffness reported in a...
February 26, 2025 03:00 ET | Source: OMass Therapeutics

OMass Therapeutics appoints Birgitte Volck as Non-Executive Director

OMass Therapeutics appoints Birgitte Volck as Non-Executive Director Oxford, United Kingdom – 26 February 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying...
February 25, 2025 09:20 ET | Source: Femasys Inc.

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

--Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners-- ATLANTA, Feb. 25, 2025 ...
February 25, 2025 09:00 ET | Source: Fuse Vectors

Fuse Vectors secures $5.2m to advance cell-free gene therapy technology, led by HCVC

Copenhagen, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Gene therapy's biggest obstacle isn't science - it's manufacturing. While the field races forward with breakthrough treatments, production remains stuck...
February 25, 2025 08:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Grand Cayman, Cayman Islands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA...
February 25, 2025 08:00 ET | Source: Upstream Bio

Upstream Bio to Present at Upcoming March Investor Conferences

Upstream Bio to Present at Upcoming March Investor Conferences
February 24, 2025 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Management to host conference call on Thursday, March 6, 2025, at 8:30 am ET FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical...
February 24, 2025 08:00 ET | Source: Cannara Biotech (Québec) Inc.

Cannara annonce la prolongation de sa convention de crédit avec BMO et de sa débenture convertible afin d’accroître sa flexibilité financière et de soutenir la mise en œuvre de sa stratégie à long terme

MONTRÉAL, 24 févr. 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous » ou « notre ») (TSXV : LOVE) (OTCQB : LOVFF) (FRA : 8CB0), producteur verticalement...
February 24, 2025 08:00 ET | Source: Cannara Biotech (Québec) Inc.

Cannara Announces Extension of BMO Credit Facility and Convertible Debenture to Enhance Financial Flexibility and Support Execution of its Long-Term Strategy

Cannara Biotech extends BMO credit to 2027, Olymbec debenture to 2028, partners with Integral for market-making, Impaq for IR
February 24, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference